Abstracts tagged "Dermatology"

Abstract Number: 0574 • ACR Convergence 2025
Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Richard G. Langley¹, Joseph F Merola², Diamant Thaçi³, Emi Nishida⁴, Bruce Strober⁵, Richard B. Warren⁶, José M. López Pinto⁷, Christina Crater⁸, Sarah Kavanagh⁸ and Paolo Gisondi⁹, ¹Dalhousie University, Halifax, NS, Canada, ²Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ³Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁴Nagoya City West Medical Center, Nagoya, Japan, ⁵Department of Dermatology, Yale University, New Haven, and Central Connecticut Dermatology Research, Cromwell, CT, ⁶Dermatology Centre, Northern Care Alliance, NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ⁷UCB, Madrid, Spain, ⁸UCB, Morrisville, NC, ⁹Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Psoriatic arthritis (PsA) affects up to one-third of patients with psoriasis;1 early identification and intervention for patients with psoriasis and risk factors (RFs) for…
Abstract Number: 2409 • ACR Convergence 2025
Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
Joseph F Merola¹, Weihong Yang², Qianyun Li², Helen Doll³, Jason Randall³, Catherine Barbey⁴ and Feng Zeng², ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Biogen, Cambridge, MA, ³Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom, ⁴Biogen, Baar, Switzerland
Background/Purpose: The Cutaneous Lupus Activity Investigator’s Global Assessment-Revised (CLA-IGA-R) is an emerging clinician-reported outcome measure for severity of Cutaneous Lupus Erythematosus (CLE) disease activity, developed…
Abstract Number: 0562 • ACR Convergence 2025
Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Joseph F Merola¹, Philip J. Mease², Laura Coates³, Iain McInnes⁴, Peter Nash⁵, Alexis Ogdie⁶, Lihi Eder⁷, mitsumasa kishimoto⁸, Anna Beutler⁹, Konstantina Psachoulia⁹, Shihong Sheng¹⁰, Bei Zhou¹¹, Mehrdad Javidi¹², Chandni Valiathan¹², Charles Iaconangelo¹⁰, Ya-Wen Yang¹³, Arun Kannan¹³, Chetan S. Karyekar⁹ and Tasneam Shagroni⁹, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Griffith University and U of Queensland, Maroochydore, Queensland, Australia, Queensland, Australia, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Toronto, Toronto, ON, Canada, ⁸Kyorin University School of Medicine, Tokyo, Japan, ⁹Johnson & Johnson, Spring House, PA, USA, Spring House, ¹⁰Johnson & Johnson, Chesterbrook, PA, USA, Chesterbrook, ¹¹Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹²Johnson & Johnson, San Diego, CA, USA, San Diego, ¹³Johnson & Johnson, San Diego, CA, USA, San Diego, CA
Background/Purpose: PsA affects ~20-30% of pts with PsO, causing articular inflammation/damage, and impaired health-related quality of life (HRQoL). ICO, a novel targeted oral peptide that…
Abstract Number: 2374 • ACR Convergence 2025
Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada
Andrew Blauvelt¹, Saakshi Khattri², Phoebe Rich³, Ronald Vender⁴, Kenneth B. Gordon⁵, Balint Szilagyi⁶, Heather Herr⁷, Bertram Knapp⁶, Delphine Deherder⁸, Sarah Kavanagh⁹ and Kim Papp¹⁰, ¹Blauvelt Consulting, LLC, Portland, OR, ²The Mount Sinai Hospital, New York, NY, ³Oregon Dermatology and Research Center, Portland, OR, ⁴Dermatrials Research Inc., Hamilton, ON, Canada, ⁵Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁶UCB, Monheim am Rhein, Germany, ⁷UCB, Smyrna, GA, ⁸UCB, Braine-l'Alleud, Belgium, ⁹UCB, Morrisville, NC, ¹⁰Probity Medical Research and Alliance Clinical Trials, Waterloo, and Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Given the chronic nature of psoriasis, and the loss of response observed with biologic therapies over time, it is crucial to establish the long-term…
Abstract Number: 0551 • ACR Convergence 2025
Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis
Victor Cazac¹ and Eugeniu Russu², ¹Norwalk Hospital, Nuvance Health, Connecticut, ²"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops insidiously from psoriasis (PsO), with enthesitis representing a critical initial site of inflammation. Musculoskeletal ultrasonography (MSUS) enables the identification of…
Abstract Number: 2345 • ACR Convergence 2025
Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
Dafna D. Gladman¹, Lihi Eder², Carlo Selmi³, Philip J. Mease⁴, Alexis Ogdie⁵, Karissa Lozenski⁶, Mohamed Sharaf⁷, Emmanouil Rampakakis⁸, Laura Pina Vegas⁹ and Laura Coates¹⁰, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Humanitas University, Milan, Italy, ⁴Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Johnson & Johnson, Horsham, PA, ⁷Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ⁸JSS Medical Research, Montréal, QC, Canada, ⁹Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), University Paris-Est Créteil Val de Marne, Créteil, France; Rheumatology, Hospital Henri Mondor, AP-HP, Créteil, France, Creteil, France, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Previous research has shown that women with psoriatic arthritis (PsA) often have lower rates of clinical response to medication but less severe radiographic joint…
Abstract Number: 0875 • ACR Convergence 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield¹, Ricardo Galimberti², Adelaide Hebert³, Wen-Hui Wang⁴, Jennifer Soung⁵, Nina Magnolo⁶, John Browning⁷, Angela Moore⁸, Mark Lebwohl⁹, Dagmar Wilsmann-Theis¹⁰, Joseph F Merola¹¹, Georgios Kokolakis¹², Dariusch Mortazawi¹³, Parbeer Grewal¹⁴, Megan Miller¹⁵, Joseph Cafone¹⁶, Shu Li¹⁷, Gigi Jiang¹⁷, Fabio Nunes¹⁷, Cynthia DeKlotz¹⁸ and Amy Paller¹⁹, ¹University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, ²Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ³University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, ⁴Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), ⁵Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁶University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁷Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, ⁸Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹³Clinical Research Center, Remscheid, Germany, Remscheid, Germany, ¹⁴University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, ¹⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ¹⁶Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ¹⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁸Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL
Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
Abstract Number: 2323 • ACR Convergence 2025
Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
Mitndbaim Parra¹, Marta Flores², María Ángeles Puche-Larrubia³, Alejandro Escudero Contreras⁴, María Dolores López-Montilla⁵ and Clementina López Medina⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Spain, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Psoriatic Arthritis (PsA) is a chronic rheumatic disease that develops in up to one-third of patients with psoriasis. Identifying predictive factors for PsA in…
Abstract Number: 0848 • ACR Convergence 2025
Spatial Frequency Domain Imaging (SFDI) for Skin Assessment in Systemic Sclerosis: Insights from Histology and Clinical Correlates
Hung Vo¹, Aarohi Mehendale², Martin Azzam³, Fatima-Ezzahrae El Adili⁴, Rutvi Patel³, Marcin TROJANOWSKI³, Michael York⁵, Eugene Kissin⁶, Jeffrey Browning⁷, Jag Bhawan³, Darren Roblyer⁵ and Andreea Bujor⁵, ¹Boston Medical Center, Peabody, MA, ²Department of Biomedical Engineering, Boston University, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Boston University School of Medicine, Revere, MA, ⁵Boston University, Boston, MA, ⁶Boston University, Newton, MA, ⁷Boston University School of Medicine, Cambridge, MA
Background/Purpose: Assessing skin involvement in systemic sclerosis (SSc) is complex, with no single method capturing all pathological changes. The modified Rodnan Skin Score (mRSS) is…
Abstract Number: 2170 • ACR Convergence 2025
I Know It When I See It! Improving Visual Diagnosis Education in Rheumatology Fellowship Training
Amarjyot Randhawa¹, Laura Nichols², Jason Kolfenbach³, Meredith Morcos² and Steven Taylor³, ¹University of Colorado Anschutz Medical Campus, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado, Denver, CO
Background/Purpose: Visual diagnosis, based on both physical exam and imaging studies, is of great importance in clinical practice and for board exam purposes in rheumatology.…
Abstract Number: 0790 • ACR Convergence 2025
Diabetes Risk in Psoriasis Patients Treated with Biologic Disease-Modifying Antirheumatic Drugs: Target Trial Emulation Using Nationwide Data
Arjun Mahajan¹, David Bates², Vinod Nambudiri³, Avery LaChance², Jeffrey Sparks⁴ and Evan Piette³, ¹Harvard Medical School, Boston, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Psoriasis is a chronic inflammatory skin disease associated with increased risk of metabolic complications, such as diabetes mellitus. However, the impact of specific biologic…
Abstract Number: 2165 • ACR Convergence 2025
Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study
Rachel Guess¹, Megan Curran², Lisa Zickuhr³ and Rachel Moquin¹, ¹Washington University School of Medicine, St. Louis, MO, ²University of Colorado | Children's Hospital Colorado, Aurora, CO, ³Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Juvenile scleroderma (JS) is an autoimmune disease that can cause skin sclerosis leading to deformity, disability, and early mortality especially with delayed diagnosis. A…
Abstract Number: 0285 • ACR Convergence 2025
Delayed-Onset Myopathy in Dermatomyositis: A Retrospective Cohort Study
Connor Buechler¹, Nawang Singhe², Lindsey Wanberg², Cody Rasner², Joseph McGrath², Karen Baker-James², Rebecca Freese² and David Pearson³, ¹University of Minnesota, Mendota Heights, MN, ²University of Minnesota, Minneapolis, MN, ³Department of Dermatology, University of Minnesota, Minneapolis, MN
Background/Purpose: Amyopathic dermatomyositis (ADM) is a subset of DM in which cutaneous findings occur without muscle disease for >6 months after diagnosis. However, there is…
Abstract Number: 1956 • ACR Convergence 2024
Artificial Intelligence Enhanced Analysis of Nailfold Capillaries by Dermatoscopy in Rheumatology Centers
Genessis Maldonado¹, Eduardo Ramos-ibañez², Borja del Carmelo Gracia-Tello³, Radic Mislav⁴ and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Zaragoza, Zaragoza, Spain, ³Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, ⁴University Hospital of Split, Split, Croatia
Background/Purpose: The use of dermatoscopes in rheumatology has been established for several years. However, the application of artificial intelligence for the detection of abnormalities in…
Abstract Number: 1977 • ACR Convergence 2024
Three-dimensional Stereophotogrammetry Has Utility in Tracking Upper Eyelid Involvement and Overall Disease Worsening in Patients with Craniofacial Localized Scleroderma
Tyler Cepica¹, Jennifer Foster², Priya Sarlashkar², Rami Hallac³ and Heidi Jacobe², ¹University of Texas Southwestern Medical School, Benbrook, TX, ²The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, ³The University of Texas Southwestern Medical Center, Department of Pastic Surgery, Dallas, TX
Background/Purpose: Craniofacial localized scleroderma’s (LoS) indolent and subtle course poses challenges in quantifying disease progression. Traditional serial photography and the Localized Scleroderma Cutaneous Assessment Tool…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].